SymbioCellTech is a biotechnology company that has developed a patented, proprietary therapy to cure insulin-dependent Type I diabetes Mellitus (T1DM), which is commonly referred to as Type 1 or juvenile onset diabetes. In summary it is been shown that through an intra-abdominal administration of SymbioCellTech Neo-Islets™ (NIs; a cellulartherapeutic) has been shown in multiple animal models of Type 1 Diabetes to result in long-term glucose control with reduced or no need for insulin injections, and with no need for toxic antirejection drugs. The durable blood glucose control along with the absence of an immune response demonstrate that NIs provide protection from autoimmune attacks that ordinarily destroy insulin-producing cells in Type 1 Diabetes, and provide an endogenous and physiologic source of insulin.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

SymbioCellTech, LLC

Christof Westenfelder

Russ Reiss

Jim Horton

Axel Zander

Anna Gooch

Leanne Swenson

Travis Manning

The Leadership Team at SymbioCellTech, LLC is responsible for steering the company's strategic direction and overseeing the development of its innovative therapy for Type 1 diabetes. This team collaborates on key initiatives, including advancing clinical trials, securing funding and partnerships, and ensuring regulatory compliance, while fostering a culture of scientific excellence and organizational growth. Their collective expertise drives the vision of delivering groundbreaking solutions to improve the lives of individuals affected by insulin-dependent diabetes.

Leadership Team

Advisory and Governance Team

Leadership Team

About

Team members

Other teams at SymbioCellTech, LLC

Advisory and Governance Team